UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer

International journal of molecular sciences, 2019-03, Vol.20 (5), p.1115

2019

Volltextzugriff (PDF)

CAR T-Cell Therapy in Hematological Malignancies

International journal of molecular sciences, 2021-08, Vol.22 (16), p.8996

2021

Volltextzugriff (PDF)

T cells in multiple myeloma display features of exhaustion and senescence at the tumor site

Journal of hematology and oncology, 2016-11, Vol.9 (1), p.116-116, Article 116

2016

Volltextzugriff (PDF)

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry

Breast cancer research : BCR, 2021-12, Vol.23 (1), p.112-112, Article 112

2021

Volltextzugriff (PDF)

Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma

International journal of molecular sciences, 2021-05, Vol.22 (9), p.4981

2021

Volltextzugriff (PDF)

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Haematologica (Roma), 2022-09, Vol.107 (9), p.2108-2120

2022

Volltextzugriff (PDF)

Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators

Current cancer drug targets, 2021-01, Vol.21 (4), p.353-359

2021

Volltextzugriff (PDF)

Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence

International journal of molecular sciences, 2020-04, Vol.21 (8), p.2856

2020

Volltextzugriff (PDF)

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

Journal of clinical oncology, 2013-05, Vol.31 (14), p.1719-1725

2013

Volltextzugriff (PDF)

Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?

Cancers, 2019-02, Vol.11 (2), p.252

2019

Volltextzugriff (PDF)

The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation

Cell communication and signaling, 2017-03, Vol.15 (1), p.13-13, Article 13

2017

Volltextzugriff (PDF)

Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?

International Journal of Molecular Sciences, 2016-06, Vol.17 (7), p.1009-1009

2016

Volltextzugriff (PDF)

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer

Oncotarget, 2018-03, Vol.9 (23), p.16512-16520

2018

Volltextzugriff (PDF)

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Clinical cancer research, 2011-09, Vol.17 (18), p.6012-6020

2011

Volltextzugriff (PDF)

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

Journal of clinical oncology, 2013-07, Vol.31 (20), p.2586-2592

2013

Volltextzugriff (PDF)

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

Journal of clinical oncology, 2012-03, Vol.30 (9), p.921-929

2012

Volltextzugriff (PDF)

The effect of exercise training on endothelial function in postmenopausal women with breast cancer under aromatase inhibitor therapy

Cancer medicine (Malden, MA), 2022-12, Vol.11 (24), p.4946-4953

2022

Volltextzugriff (PDF)

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

The Lancet (British edition), 2012-05, Vol.379 (9828), p.1791-1799

2012

Volltextzugriff (PDF)

1 – 25 von 980

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(929)
Mit Volltextzugriff
(891)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(533)
Life Sciences & Biomedicine
(517)
Humans
(411)
Oncology
(320)
Female
(257)
Middle Aged
(232)
Aged
(214)
Male
(202)
Adult
(182)
Hematology
(161)
Aged, 80 And Over
(111)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(108)
Chemotherapy
(105)
Patients
(99)
Tumors
(98)
Treatment Outcome
(97)
Biological And Medical Sciences
(92)
Medical Sciences
(90)
Prognosis
(88)
Medicine
(82)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(186)
Journal Of Clinical Oncology
(99)
Cancer Research
(39)
British Journal Of Haematology
(25)
Memo - Magazine Of European Medical Oncology
(25)
Clinical Cancer Research
(22)
The Lancet Oncology
(21)
The New England Journal Of Medicine
(21)
Annals Of Hematology
(19)
Anticancer Research
(15)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer

CAR T-Cell Therapy in Hematological Malignancies

T cells in multiple myeloma display features of exhaustion and senescence at the tumor site

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry

Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators

Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence

Gemtuzumab Ozogamicin in NPM1 -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?

The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation

Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

The effect of exercise training on endothelial function in postmenopausal women with breast cancer under aromatase inhibitor therapy

Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial

Suchergebnisse filtern